In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or the participants are unable to tolerate the study drugs. - "Our study unveiled the essential purpose in the KLF16/MYC regulatory axis in https://abbv-744forsmallcelllungc69124.blog-a-story.com/12481934/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained